Peng, C.; Rabold, K.; Netea, M.G.; Jaeger, M.; Netea-Maier, R.T.
Influence of Lenvatinib on the Functional Reprogramming of Peripheral Myeloid Cells in the Context of Non-Medullary Thyroid Carcinoma. Pharmaceutics 2023, 15, 412.
https://doi.org/10.3390/pharmaceutics15020412
AMA Style
Peng C, Rabold K, Netea MG, Jaeger M, Netea-Maier RT.
Influence of Lenvatinib on the Functional Reprogramming of Peripheral Myeloid Cells in the Context of Non-Medullary Thyroid Carcinoma. Pharmaceutics. 2023; 15(2):412.
https://doi.org/10.3390/pharmaceutics15020412
Chicago/Turabian Style
Peng, Chunying, Katrin Rabold, Mihai G. Netea, Martin Jaeger, and Romana T. Netea-Maier.
2023. "Influence of Lenvatinib on the Functional Reprogramming of Peripheral Myeloid Cells in the Context of Non-Medullary Thyroid Carcinoma" Pharmaceutics 15, no. 2: 412.
https://doi.org/10.3390/pharmaceutics15020412
APA Style
Peng, C., Rabold, K., Netea, M. G., Jaeger, M., & Netea-Maier, R. T.
(2023). Influence of Lenvatinib on the Functional Reprogramming of Peripheral Myeloid Cells in the Context of Non-Medullary Thyroid Carcinoma. Pharmaceutics, 15(2), 412.
https://doi.org/10.3390/pharmaceutics15020412